Figure 4.

Effect of WAY100635 (0.1 mg·kg⁻¹) or SAL administered i.p. 15 min prior to CBDA (0.1 mg·kg⁻¹ i.p.) or VEH in LiCl-treated rats. The number of conditioned gaping responses was measured during the test trial (A). Each bar represents the mean number of conditioned gaping responses ± SEM (n = 12). The cumulative amount of saccharin solution consumed (mL ± SEM) during a one-bottle consumption test was measured at 30, 120 and 360 min after introduction of the bottle to fluid-restricted rats (B). Individual one-way anovas for each time point indicate that there is no significant difference between any of the four pretreatment groups (P > 0.05). The asterisks indicate a significant difference from the SAL-VEH-treated control animals (***P < 0.001; one-way anova).